These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9614834)

  • 1. Leprosy reactions--complications of steroid therapy.
    Sugumaran DS
    Int J Lepr Other Mycobact Dis; 1998 Mar; 66(1):10-5. PubMed ID: 9614834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leprosy reactions: humoral and cellular immune responses to M. leprae, 65kDa, 28kDa, and 18 kDa antigens.
    Mohanty KK; Joshi B; Katoch K; Sengupta U
    Int J Lepr Other Mycobact Dis; 2004 Jun; 72(2):149-58. PubMed ID: 15301588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Some considerations on the origin of type 1 reactions in leprosy.
    Opromolla DV
    Int J Lepr Other Mycobact Dis; 2005 Mar; 73(1):33-4. PubMed ID: 15898839
    [No Abstract]   [Full Text] [Related]  

  • 4. [The collateral effects of prolonged corticosteroid therapy].
    Genova R
    Minerva Pediatr; 1969 Oct; 21(43):2026-38. PubMed ID: 4326808
    [No Abstract]   [Full Text] [Related]  

  • 5. The risk of standardized regimens of corticosteroids for the treatment of leprosy reactions in the field.
    Richardus JH; Smith WC
    Lepr Rev; 1995 Dec; 66(4):328-9. PubMed ID: 8637390
    [No Abstract]   [Full Text] [Related]  

  • 6. A comparative and combinatorial study on two serological assays for detection of Mycobacterium leprae infection.
    Parkash O; Girdhar BK
    Acta Leprol; 2001-2002; 12(2):63-9. PubMed ID: 12136738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Side-effects of corticosteroid agents.
    Seale JP; Compton MR
    Med J Aust; 1986 Feb; 144(3):139-42. PubMed ID: 3511355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring the effects of preventive therapy in the Federated States of Micronesia.
    Cho SN; Walsh GP; Brennan PJ
    Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4 Suppl):S19-22. PubMed ID: 10700932
    [No Abstract]   [Full Text] [Related]  

  • 9. Lymphoproliferative responses of leprosy patients and healthy controls to nitrocellulose-bound M. leprae antigens.
    Sachdeva G; Kaur G; Bhutani LK; Bamezai RN
    Int J Lepr Other Mycobact Dis; 1999 Jun; 67(2):133-42. PubMed ID: 10472365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of costimulatory molecules (CD80, CD86, CD28, CD152), accessory molecules (TCR alphabeta, TCR gammadelta) and T cell lineage molecules (CD4+, CD8+) in PBMC of leprosy patients using Mycobacterium leprae antigen (MLCWA) with murabutide and T cell peptide of Trat protein.
    Sridevi K; Neena K; Chitralekha KT; Arif AK; Tomar D; Rao DN
    Int Immunopharmacol; 2004 Jan; 4(1):1-14. PubMed ID: 14975355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Side-effects of corticosteroid therapy (author's transl)].
    Karl HJ
    MMW Munch Med Wochenschr; 1980 Aug; 122(35):1191-4. PubMed ID: 6780800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of anti-PGL-I as a prognostic marker of leprosy reaction.
    Stefani MM; Martelli CM; Morais-Neto OL; Martelli P; Costa MB; de Andrade AL
    Int J Lepr Other Mycobact Dis; 1998 Sep; 66(3):356-64. PubMed ID: 9934362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ML0405 and ML2331 are antigens of Mycobacterium leprae with potential for diagnosis of leprosy.
    Reece ST; Ireton G; Mohamath R; Guderian J; Goto W; Gelber R; Groathouse N; Spencer J; Brennan P; Reed SG
    Clin Vaccine Immunol; 2006 Mar; 13(3):333-40. PubMed ID: 16522774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum samples from patients with mycobacterial infections cross-react with HIV structural proteins Gp41, p55 and p18.
    Hussain T; Sinha S; Katoch K; Yadav VS; Kulshreshtha KK; Singh I; Sengupta U; Katoch VM
    Lepr Rev; 2007 Jun; 78(2):137-47. PubMed ID: 17824484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative characterization of the antigenic composition of M. leprae and M. lufu].
    Salamatina OS; Diachina MN; Iushchenko AA; Chernousova LN; Kalinina ON; Parshin MP
    Probl Tuberk; 2001; (8):49-51. PubMed ID: 11767394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clarification to Rada-Schlaefli, et al.
    Iyer A; Mistry N; Antia N; Harboe M
    Int J Lepr Other Mycobact Dis; 2000 Mar; 68(1):63-4. PubMed ID: 10834071
    [No Abstract]   [Full Text] [Related]  

  • 17. Antibody response to phenolic glycolipid I and Mycobacterium w antigens and its relation to bacterial load in M. leprae-infected mice and leprosy patients.
    Moudgil KD; Gupta SK; Naraynan PR; Srivastava LM; Mishra RS; Talwar GP
    Clin Exp Immunol; 1989 Nov; 78(2):214-8. PubMed ID: 12412751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Management of complications of steroid therapy].
    Hara M; Sasaki H
    Nihon Rinsho; 1984 Nov; 42(11):2516-9. PubMed ID: 6442370
    [No Abstract]   [Full Text] [Related]  

  • 19. Rational combination of peptides derived from different Mycobacterium leprae proteins improves sensitivity for immunodiagnosis of M. leprae infection.
    Geluk A; van der Ploeg J; Teles RO; Franken KL; Prins C; Drijfhout JW; Sarno EN; Sampaio EP; Ottenhoff TH
    Clin Vaccine Immunol; 2008 Mar; 15(3):522-33. PubMed ID: 18199740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 1 reaction in leprosy: a model for a better understanding of tissue immunity under an immunopathological condition.
    Andrade PR; Pinheiro RO; Sales AM; Illarramendi X; Barbosa MG; Moraes MO; Jardim MR; Nery JA; Sampaio EP; Sarno EN
    Expert Rev Clin Immunol; 2015 Mar; 11(3):391-407. PubMed ID: 25666357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.